RE:RE:Next...Thanks mercedesman, I appreciate the reply.. It sounds like there is little immediate pressure on Spectral to sell and they could comfortably wait until after approval. The Carlyle Group, on the other hand, might want to lock a deal down as soon as it's practical to do so.
mercedesman wrote: Hey g
While that's certainly possible, it's likely going to be kept under wraps. Not Spectral's style to talk about any ongoing negotiations.
The other thing to think about is whether any potential suitor would be looking for any kind of uncertainty discount. If too high, then it may behoove Spectral to wait it out in order to maximize shareholder value .
discount milestones?
- Completion of enrolment ( Oct-Dec, 2024)
- release of top line data ( Feb to April? 2025)
- final FDA ruling ( mid 2025?)
Given the open label nature of the Trial, I'm sure that any potential suitors capable of doing their homework could be convinced to sharpen their pencil and make a fair move without 100% certainty.
MM